UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 207

Sortiert nach

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1254-1261

2010

Volltextzugriff (PDF)

Adaptive mutability of colorectal cancers in response to targeted therapies

Science (American Association for the Advancement of Science), 2019-12, Vol.366 (6472), p.1473-1480

2019

Volltextzugriff (PDF)

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Volltextzugriff (PDF)

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical cancer research, 2019-05, Vol.25 (10), p.3046-3053

2019

Volltextzugriff (PDF)

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Journal of clinical oncology, 2013-02, Vol.31 (6), p.759-765

2013

Volltextzugriff (PDF)

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5705-5712

2008

Volltextzugriff (PDF)

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4697-4705

2010

Volltextzugriff (PDF)

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (6), p.2643-2648

2007

Volltextzugriff (PDF)

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1626-1634

2008

Volltextzugriff (PDF)

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Journal of clinical oncology, 2008-09, Vol.26 (25), p.4217-4219

2008

Volltextzugriff (PDF)

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1658-1664

2007

Volltextzugriff (PDF)

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2004-07, Vol.351 (4), p.337-345

2004

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3238-3245

2007

Volltextzugriff (PDF)

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1619-1625

2008

Volltextzugriff (PDF)

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Cancer, 2009-04, Vol.115 (7), p.1544-1554

2009

Volltextzugriff (PDF)

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Journal of clinical oncology, 2005-12, Vol.23 (35), p.8942-8949

2005

Volltextzugriff (PDF)

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS4124-TPS4124

2020

Volltextzugriff (PDF)

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5335-5343

2008

Volltextzugriff (PDF)

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1360-1377

2000

Volltextzugriff (PDF)

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3594-3594

2018

Volltextzugriff (PDF)

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Journal of clinical oncology, 2016-03, Vol.34 (7), p.e54-e56

2016

Volltextzugriff (PDF)

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3508-3508

2015

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Journal of clinical oncology, 2024-01, Vol.42 (1), p.47

2024

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

KollektionEZB Electronic Journals Library

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(199)

Publikationsform

Artikel
(207)

Sprache

Englisch
(207)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Humans
(72)
Science & Technology
(71)
Life Sciences & Biomedicine
(68)
Oncology
(54)
Biological And Medical Sciences
(45)
Medical Sciences
(44)
Male
(38)
Female
(37)
Middle Aged
(32)
Tumors
(31)
Adult
(28)
Aged
(27)
Gastroenterology. Liver. Pancreas. Abdomen
(20)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(20)
Colorectal Neoplasms - Drug Therapy
(18)
Colorectal Neoplasms - Genetics
(18)
Disease-Free Survival
(16)
Treatment Outcome
(15)
Aged, 80 And Over
(14)
Antibodies, Monoclonal - Therapeutic Use
(14)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Publisher
(207)
LWW Total
(137)
MEDLINE
(73)
IngentaConnect Journals
(46)
Ingenta.com
(45)
Wiley Online Library All Journals
(12)
Wiley Online Library
(12)
HEAL-Link subscriptions: Springer Book Series
(10)
APS_美国物理学会期刊
(2)
APS_美国物理学会过刊
(2)
Science Online_科学在线
(1)
JSTOR
(1)
Nexis Uni (LexisNexis)
(1)
Nature_系列刊
(1)

9 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Adaptive mutability of colorectal cancers in response to targeted therapies

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

International harmonization of diagnostic criteria for HER2 -amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Aktive Filter

Suchergebnisse filtern